Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
We are a biopharmaceutical company focused on unlocking the potential of new and existing drugs.
We began leveraging decades of clinical experience and a goal to transform the care of debilitating medical and mental health conditions. Here is the story…
Bexson Biomedical incorporated.
Bexson granted FDA orphan designation to treat CRPS with a ketamine therapy.
Contracted with Thermo Fisher Scientific to perform GMP manufacturing of Bexson’s ketamine therapy.
Completed BB106 ketamine formulation development for subcutaneous delivery.
Completed BB106 ketamine formulation development for subcutaneous delivery.
Bexson & Stevanato Group co-development agreement for a tamper-resistant wearable infusion device.
Filed 5 new provisional patent applications focused on subcutaneous delivery of psychedelic, empathogen and NMDA-receptor antagonist compounds.
Launched Project Hermes to develop proprietary formulations of existing psychedelic compounds, designed for subcutaneous delivery.
Complete $4.8M Seed Round financing.
Initiated IND-enabling animal studies with BB106.
Launched Bexson Discovery, developing new compounds targeting the NMDA receptor.
Completed $7.3M Series A Financing.
Successful Pre-IND FDA guidance for BB106 to treat acute pain.
“USPTO Allowance of SeValent™ formulation technology” covering the application of SeVALENT to ANY molecule regardless of class.
Bexson and Partners are free to explore applications to existing drugs and new chemical entities that have yet to be discovered.
Drug Delivery Innovation Awards – Partnership Category
2022 Universe of Pre-Filled Syringes and Injection Devices Conference, Palm Springs, CA on October 18, 2022
Developing our BB106 non-opioid therapy for pain management and leveraging our SeValent™ platform are the focus of our R&D. Bexson is poised to disrupt the $189 billion (growing to $347 billion by 2030) injectable drug delivery market.
Our SeValent™ technology provides pharmacokinetic solutions for new and existing drugs across a broad range of therapeutic areas.
Our experienced team has a strong background in health innovation, clinical development and IP creation. Expertise in Pharma with Over 20 FDA Approvals and Leaders in Med-Tech Device Development with more than 130 US Patents.
We are developing a formulation technology platform & a subcutaneous delivery platform for controlled delivery of critical medications in need of pharmacokinetic innovation.
